Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 10/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | RRM1 | P23921 | 1/20 | 0.34 |
| ▸ | RRM2 | P31350 | 1/20 | 0.34 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14780646 | 1.00 | GLS (0.40) | GLSDPP4EPHX1SHBGTSHR | |
| SCHEMBL13201866 | 0.81 | GLS (0.40) | GLSDPP4EPHX1DPP7 | |
| SCHEMBL15087472 | 0.80 | DPP4 (0.41) | GLSDPP4EPHX1DPP7MMP1 | |
| SCHEMBL31074241 | 0.77 | DPP4 (0.41) | GLSDPP4ALDH1A1DPP7MMP1 | |
| SCHEMBL764548 | 0.75 | GLS (0.47) | GLSDPP4EPHX1TSHRKDM4E | |
| SCHEMBL418389 | 0.75 | MMP1 (0.38) | GLSDPP4TSHRALDH1A1MMP1 | |
| Hydrochloric Acid SCHEMBL15618896 | 0.74 | GLS (0.37) | GLSDPP4EPHX1TSHRMETAP2 | |
| SCHEMBL23394511 | 0.74 | EPHX1 (0.40) | GLSDPP4EPHX1SHBGMETAP2 | |
| Hydrochloric Acid SCHEMBL15618898 | 0.74 | MMP1 (0.38) | GLSDPP4TSHRALDH1A1MMP1 | |
| Hydrochloric Acid SCHEMBL15619093 | 0.74 | MMP1 (0.38) | GLSDPP4TSHRALDH1A1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100174077-A1 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100063252-A1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063252-A1 | PROCESSES AND INTERMEDIATES | TFPI, SPINT2, SERPINB1 | GLS 2355/4885DPP4 69/4885EPHX1 724/4885 |
| US-20100174077-A1 | Processes and intermediates | TFPI, SPINT2, SERPINB1 | GLS 2355/4885DPP4 69/4885EPHX1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.